Even as the recent euphoria surrounding a cancer vaccine breakthrough from Moderna (MRNA) takes a pause, investors are increasing their bets on cancer treatment name Exelixis (EXEL). The stock's breakout on Wednesday makes it the IBD 50 Stocks To Watch pick. Exelixis shares hit an all-time high Wednesday.
The stock's relative strength line is rising as it clears a third-stage…
Extract — continue reading at the source.
Related stories
I offered to buy my friend a birthday drink. She ordered $180 worth of food and expects me to pay. Should I Venmo her for half?
OpenAI’s $300B Deal Could Make Oracle the Weak Link in the AI Boom
She Retired at 62 and Kept a $30,000 Part-Time Job. Social Security Withheld $2,760 That Year. She Never Found Out Why.
U.S. Debt, AI Borrowing Binge Spurs Bessent's Bond Market Gambit; Risks Rise For Stocks, Dollar
Crypto Groups Push SEC for Tailored Rules on Novel ETFs
2 Monster Stocks to Hold for the Next 10 Years